Reply

Pm, Mertès; Demoly, Pascal; Alpérovitch, Annick; Bazin, A.; Bienvenu, Jacques; Caldani, C.; Lamy, B.; Laroche, D.; Mf, Leconte des Floris; Jy, Py; Drouet, Christian; Carlier, M.; Lienhart, A.

doi:10.1016/j.jaci.2012.11.047

Cited by 1 publication

(1 citation statement)

References 3 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, when limited to the years in which MB/light-treated plasma was actually used (2008)(2009)(2010), statistical analysis of the updated 2010 haemovigilance data did not confirm a significantly higher incidence of severe allergic reactions with MB/light plasma than with other types of plasma . A recent analysis including the 2011 haemovigilance data revealed a trend with borderline significance towards a higher incidence of severe allergic reactions with MB/light plasma (Mertes et al, 2013). The variability of these data demonstrates that imbalances in use and the effects of slight variations in incidence on statistical outcome have to be carefully considered when analysing and interpreting data on very rare events.…”

Section: Plasmamentioning

confidence: 99%

Update on the use of pathogen‐reduced human plasma and platelet concentrates

Seltsam

Müller

2013

Br J Haematol

View full text Add to dashboard Cite

SummaryThe use of pathogen reduction technologies (PRTs) for labile blood components is slowly but steadily increasing. While pathogen-reduced plasma is already used routinely, efficacy and safety concerns impede the widespread use of pathogen-reduced platelets. The supportive and often prophylactic nature of blood component therapy in a variety of clinical situations complicates the clinical evaluation of these novel blood products. However, an increasing body of evidence on the clinical efficacy, safety, cost-benefit ratio and development of novel technologies suggests that pathogen reduction has entered a stage of maturity that could further increase the safety margin in haemotherapy. This review summarizes the clinical evidence on PRTs for plasma and platelet products that are currently licensed or under development.

show abstract

Section: Plasmamentioning

confidence: 99%